T1	Participants 298 363	patients with diarrhea-dominant irritable bowel syndrome (IBS-D).
T2	Participants 643 657	IBS-D patients
T3	Participants 717 750	Thirty-seven patients received S.
T4	Participants 751 798	boulardii and 35 patients received the placebo.
T5	Participants 1845 1867	of patients with IBS-D
